We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merit Medical Hits 52-Week High: What's Driving the Stock?
Read MoreHide Full Article
Share price of South Jordan, UT-based Merit Medical Systems, Inc. (MMSI - Free Report) reached a fresh 52-week high of $26.80 on Dec 9, finally closing a tad lower at $26.60. Currently, Merit Medical carries a Zacks Rank #3 (Hold).
Among the major positives, the stock rallied 43.9% over the past one year, whereas the S&P 500’s grew only 12.3% over the same time frame. It has added roughly 43.1% year to date. Average volume of shares traded over the last three months was remarkable at approximately 326.9k. The stock has a market cap of $1.19 billion. For the majority of the last six months, Merit Medical’s share price trend has considerably outperformed the Zacks categorized Medical/ Dental Supplies sub-industry.
In fact, after posting a stupendous third-quarter 2016 and beating the Zacks Consensus Estimates, shares of Merit Medical have gained almost 18% till Friday’s close.
In the last one month, the stock has gained 15.7%, whereas Medical/Dental Supplies Markets has increased 1.5%.
Positive Estimate Revisions
The estimate revision trend for the current year seems quite favorable for the stock at the moment, with three estimates moving up in the last one month.
The Zacks Consensus Estimate for fiscal 2016 inched up by 2 cents to a penny, over the last 60 days.
Key Catalysts
The leading manufacturer and marketer of proprietary disposable devices, Merit Medical recently announced that it has received 510(k) clearance for SwiftNINJA Steerable Microcatheter from the U.S. FDA.
Notably, the SwiftNINJA platform is expected to be launched shortly, along with the company’s highly exclusive Corvocet Biopsy System, which has also received the 510(k) clearance.
Earlier this year, Merit Medical also received a 510(k) clearance from the FDA for the Elation Pulmonary Dilation Balloon, which is again a key positive.
We are upbeat about Merit Medical’s HeRo platform. The launch of the proprietary – Super HeRO and HeRO Ally products – in October, also buoyed the company with significant opportunities. Notably, the HeRo product line was acquired by Merit Medical from CryoLife earlier this year. Per management, the ‘Think HeRO Graft Training program’ in the HeRo platform is likely to provide substantial opportunity to the company over the long run.
We are also upbeat about long-term expected growth of the stock which is pegged at 12.5% and projected sales growth of 12.04%, much higher than the industry average of 5.3%. Additionally, positive earnings estimate revisions for 2016, along with a solid expected earnings growth rate, indicate the stock’s potential for further price appreciation in the near term.
Key Picks
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. .
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of almost 37.4%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 19.9% in the last three months.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of almost 51.3%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merit Medical Hits 52-Week High: What's Driving the Stock?
Share price of South Jordan, UT-based Merit Medical Systems, Inc. (MMSI - Free Report) reached a fresh 52-week high of $26.80 on Dec 9, finally closing a tad lower at $26.60. Currently, Merit Medical carries a Zacks Rank #3 (Hold).
Among the major positives, the stock rallied 43.9% over the past one year, whereas the S&P 500’s grew only 12.3% over the same time frame. It has added roughly 43.1% year to date. Average volume of shares traded over the last three months was remarkable at approximately 326.9k. The stock has a market cap of $1.19 billion. For the majority of the last six months, Merit Medical’s share price trend has considerably outperformed the Zacks categorized Medical/ Dental Supplies sub-industry.
In fact, after posting a stupendous third-quarter 2016 and beating the Zacks Consensus Estimates, shares of Merit Medical have gained almost 18% till Friday’s close.
In the last one month, the stock has gained 15.7%, whereas Medical/Dental Supplies Markets has increased 1.5%.
Positive Estimate Revisions
The estimate revision trend for the current year seems quite favorable for the stock at the moment, with three estimates moving up in the last one month.
The Zacks Consensus Estimate for fiscal 2016 inched up by 2 cents to a penny, over the last 60 days.
Key Catalysts
The leading manufacturer and marketer of proprietary disposable devices, Merit Medical recently announced that it has received 510(k) clearance for SwiftNINJA Steerable Microcatheter from the U.S. FDA.
MERIT MEDICAL Price and Consensus
MERIT MEDICAL Price and Consensus | MERIT MEDICAL Quote
Notably, the SwiftNINJA platform is expected to be launched shortly, along with the company’s highly exclusive Corvocet Biopsy System, which has also received the 510(k) clearance.
Earlier this year, Merit Medical also received a 510(k) clearance from the FDA for the Elation Pulmonary Dilation Balloon, which is again a key positive.
We are upbeat about Merit Medical’s HeRo platform. The launch of the proprietary – Super HeRO and HeRO Ally products – in October, also buoyed the company with significant opportunities. Notably, the HeRo product line was acquired by Merit Medical from CryoLife earlier this year. Per management, the ‘Think HeRO Graft Training program’ in the HeRo platform is likely to provide substantial opportunity to the company over the long run.
We are also upbeat about long-term expected growth of the stock which is pegged at 12.5% and projected sales growth of 12.04%, much higher than the industry average of 5.3%. Additionally, positive earnings estimate revisions for 2016, along with a solid expected earnings growth rate, indicate the stock’s potential for further price appreciation in the near term.
Key Picks
Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation (ADUS - Free Report) , LHC Group, Inc. and HMS Holdings Corp. .
While Addus HomeCare and LHC Group boast a Zacks Rank #1 (Strong Buy), HMS Holdings carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of almost 37.4%.
LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 19.9% in the last three months.
HMS Holdings has an expected earnings growth of almost 14.3%. The company posted a promising year-to-date return of almost 51.3%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>